Selection of Particle Beam vs. Photon Beam Radiation Therapy for HCC: Japanese Experience = Selection of Particle Beam vs. Photon Beam Radiation Therapy for HCC: Japanese Experience
저자
( Hideyuki Sakurai ) ; ( M Iizumi ) ; ( S Shimizu ) ; ( H. Numajiri ) ; ( M. Mizumoto ) ; ( K. Nakai ) ; ( T. Okumura ) 연구자관계분석
발행기관
학술지명
권호사항
발행연도
2020
작성언어
-자료형태
학술저널
수록면
27-28(2쪽)
제공처
Radiation therapy (RT) using conventional fractionation has not been thought to be curative enough for hepatocellular carcinoma (HCC) and it has not been performed as a high priority in comparison to other standard treatments, such as surgery, percutaneous ablation and transcatheter approach. Because the liver is high sensitive to radiation, especially for patients with liver cirrhosis, non-irradiated normal liver volume must be preserved as much as possible when curative radiation is given for HCC.
Since many technological progress has been made in radiation oncology in recent years, RTs are used as an important curative treatment option for liver cancer. Stereotactic body radiotherapy (SBRT), which is included in Japanese national health insurance system, is a technique to accurately concentrate doses three-dimensionally on the target with short-term irradiation of 1-2 weeks. This technique can be used for relatively small tumors less than 5 cm with about 90% local control. Recently, Hara K. et al. reported survival result of SBRT comparing radiofrequency ablation using propensity score analysis, and they concluded that SBRT appears to be an acceptable alternative treatment option for patients who are not candidates for RFA. In addition, in Japan, muticenter prospective study of SBRT for untreated solitary primary HCC, so called STRSPH study, is ongoing. Eligible patients are untreated solitary, Child-Pugh score ≦7, Diameter: 1-5cm, UICC 7th. T1, T2, T3bN0M0, performance status score of 0-2, and 20-85 year-old. The primary endpoint / number of cases of this study are 3-year overall survival / 60 cases.
Particle beam therapy (PBT: proton beam therapy, heavy ion beam therapy) has unique character of radiation dose distribution, which is called Bragg peak. PBT can accumulate more dose to the target with minimizing normal liver dose. Primary liver tumor is an important indication that has been specified to be of the highest priority by the American Society for Radiology and Oncology (ASTRO). In fact, most of the studies on PBT for HCC are published by Japan, and rather highly evaluated abroad. Eighteen proton facilities and 6 heavy ion facilities are working now in Japan. The local control rate was approximately 90% and the 5-year survival rate was reported to be approximately 50%. According to the results of our hospital, PBT can control 90% of a large tumor of 10 cm or more. Clinical studies of PBT report favorable therapeutic effects, even for not only large tumors but also tumors in elderly patient. In addition, PBT has been clearly shown to play an important role in the treatment of HCC-related portal vein tumor thrombosis (PVTT). When applied as a curative treatment for bulky tumors with portal vein embolism, median survival time of 27 months has been obtained in our study. The clinical study comparing proton vs surgery, which is non-randomized trial using propensity score, is ongoing in Japan (JCOG1315C). Japanese Society for Radiation Oncology (JASTRO) defined identical rule for indication and treatment method in PBT for HCC, and the all data should be registered in the data-base since 2016.
We are facing an aging society, although there are indications of surgery and other local treatment, the number of patients who choose curative radiation therapy due to aging and co-existing disease is increasing. But, the history of radical RT for HCC is still short, and sufficient consensus has not been obtained regarding the criteria for its therapeutic indication. RT may become an option for curative local treatment of HCC, but no specific role for RT has been described in the Japanese treatment guidelines. In the future, it is important to proceed with research to clarify the indication of curative radiation therapy, keeping in mind the comparison with other therapies.
서지정보 내보내기(Export)
닫기소장기관 정보
닫기권호소장정보
닫기오류접수
닫기오류 접수 확인
닫기음성서비스 신청
닫기음성서비스 신청 확인
닫기이용약관
닫기학술연구정보서비스 이용약관 (2017년 1월 1일 ~ 현재 적용)
학술연구정보서비스(이하 RISS)는 정보주체의 자유와 권리 보호를 위해 「개인정보 보호법」 및 관계 법령이 정한 바를 준수하여, 적법하게 개인정보를 처리하고 안전하게 관리하고 있습니다. 이에 「개인정보 보호법」 제30조에 따라 정보주체에게 개인정보 처리에 관한 절차 및 기준을 안내하고, 이와 관련한 고충을 신속하고 원활하게 처리할 수 있도록 하기 위하여 다음과 같이 개인정보 처리방침을 수립·공개합니다.
주요 개인정보 처리 표시(라벨링)
목 차
3년
또는 회원탈퇴시까지5년
(「전자상거래 등에서의 소비자보호에 관한3년
(「전자상거래 등에서의 소비자보호에 관한2년
이상(개인정보보호위원회 : 개인정보의 안전성 확보조치 기준)개인정보파일의 명칭 | 운영근거 / 처리목적 | 개인정보파일에 기록되는 개인정보의 항목 | 보유기간 | |
---|---|---|---|---|
학술연구정보서비스 이용자 가입정보 파일 | 한국교육학술정보원법 | 필수 | ID, 비밀번호, 성명, 생년월일, 신분(직업구분), 이메일, 소속분야, 웹진메일 수신동의 여부 | 3년 또는 탈퇴시 |
선택 | 소속기관명, 소속도서관명, 학과/부서명, 학번/직원번호, 휴대전화, 주소 |
구분 | 담당자 | 연락처 |
---|---|---|
KERIS 개인정보 보호책임자 | 정보보호본부 김태우 | - 이메일 : lsy@keris.or.kr - 전화번호 : 053-714-0439 - 팩스번호 : 053-714-0195 |
KERIS 개인정보 보호담당자 | 개인정보보호부 이상엽 | |
RISS 개인정보 보호책임자 | 대학학술본부 장금연 | - 이메일 : giltizen@keris.or.kr - 전화번호 : 053-714-0149 - 팩스번호 : 053-714-0194 |
RISS 개인정보 보호담당자 | 학술진흥부 길원진 |
자동로그아웃 안내
닫기인증오류 안내
닫기귀하께서는 휴면계정 전환 후 1년동안 회원정보 수집 및 이용에 대한
재동의를 하지 않으신 관계로 개인정보가 삭제되었습니다.
(참조 : RISS 이용약관 및 개인정보처리방침)
신규회원으로 가입하여 이용 부탁 드리며, 추가 문의는 고객센터로 연락 바랍니다.
- 기존 아이디 재사용 불가
휴면계정 안내
RISS는 [표준개인정보 보호지침]에 따라 2년을 주기로 개인정보 수집·이용에 관하여 (재)동의를 받고 있으며, (재)동의를 하지 않을 경우, 휴면계정으로 전환됩니다.
(※ 휴면계정은 원문이용 및 복사/대출 서비스를 이용할 수 없습니다.)
휴면계정으로 전환된 후 1년간 회원정보 수집·이용에 대한 재동의를 하지 않을 경우, RISS에서 자동탈퇴 및 개인정보가 삭제처리 됩니다.
고객센터 1599-3122
ARS번호+1번(회원가입 및 정보수정)